Clinical Trial Search

Primary: Percent Change in Body Weight From Baseline (Day 1) to Week 26 — -9.46; -0.94 percent change in body weight — p=<0.0001

Primary: Overall Survival — 26.81; 24.97 months — p=0.831

Primary: Time to Neutrophil Recovery — 17 days

Primary: Change in Pulmonary Function, as Measured by Serial Forced Expiratory Volume in 1 Second (FEV1) on Spirometry — -0.04 Liter — p=0.2030

Primary: Progression-free Survival (PFS) — 5.59; 6.93 months

Primary: Overall Response Rate (ORR) — 11; 3 Participants

Primary: Percentage of Non-cirrhotic Treatment-Naïve Participants Who Are Eligible for Interferon (IFN)-Based Therapy and Who Have High Viral Load in the DB Active Treatment…

Primary: Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score. — -3.32; -4.35; -5.58; -3.48 Units on a scale — p=0.0093

Primary: The Difference in Seroconversion/Immunogenicity Between rHA Formulated in an oil-in- Water Adjuvant (SE) Compared to a rHA Antigen Alone. — 83; 70; 9; 76 percentage of…

Primary: FEV1 AUC0-3h Response — -0.014; 0.205; 0.285; 0.316 L — p=<0.0001

Primary: The Number of Patients Who Experience Symptomatic Intracerebral Hemorrhage (sICH). — 1 participants

Primary: Quality of Recovery — 28; 16 participants

Primary: Percentage of Participants With Intraoperative Hemostasis at Target Bleeding Site Within 3 Minutes — 80.7; 50.0; 87.5; 44.4 percentage of participants — p=<0.001

Primary: Complete and Partial Response Rate — 0; 1; 4; 11 participants

Primary: Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment — 16; 5 participants